Top 10 Pharmaceutical Companies in World 2019

Posted in Top Brand Lists, Total Reads: 16610

Pharmaceutical industry has been one of the most consistently growing sector the world over. With billions of dollars riding on the medical industry, top pharma companies have been regularly investing huge sums on research & development to have more innovative solutions in medical sciences. The leading pharma companies have a strong production and distribution of medicines, which are available at all hospitals & pharmacy stores worldwide. The best pharmaceutical companies innovate and product life saving medicines to support healthcare efforts across the world.

The list of top pharma companies include names like Pfizer, Roche, Johnson & Johnson followed by Merck, Sanofi, Novartis, AbbVie etc. Here is a list of the top 10 pharma companies in the world 2019.

Quick Glance :

Below are the top Pharmaceutical Companies in World:

1st Place : Pfizer

2nd Place : Roche

3rd Place : Johnson & Johnson

4th Place : Merck & Co

5th Place : Sanofi

6th Place : Novartis

7th Place : AbbVie

8th Place : GlaxoSmithKline

9th Place : Gilead Sciences

10th Place : Amgen

For More details about rankings and parameters on the top pharmaceutical companies, read the full article.

Top Pharmaceutical Companies with Ranking Parameters (Revenue, R&D etc):

10. Amgen

Amgen Inc is an American multinational biopharmaceutical organization headquartered in Thousand Oaks, California.

Image: Wikimedia

Amgen finds and creates inventive treatments in both biopharmaceuticals and little particle drugs. In 2017, top 3 of the line drugs incorporate Enbrel, Neulasta, and Aranesp, and for the final quarter, add up to incomes diminished 3 percent versus the final quarter of 2016 to ~6 billion.

For the entire year, add up to incomes diminished 1 percent to 22.8 billion. Generally accepted accounting principles misfortune per offer of 5.89 for the final quarter and GAAP profit per share aka Earnings per share of 2.69 for the entire year incorporate a 6.1 billion charge identified with effects of corporate expense change. Non-GAAP Earnings per share were level in the final quarter at 2.89, driven by higher working edges and intrigue wage and a lower share tally. Free income for the entire year grew 9 percent to 10.5 billion, driven by higher working salary and great changes in working capital. At year end, money and speculations totaled 41.7 billion. The Company hopes to expand speculations to drive extra volume-driven development of novel meds in extensive patient populaces. These designs incorporate another U.S. producing plant. Money to investors totaled 6.5 billion of every 2017 through profits and offer repurchases. The Company's Board of Directors approved an extra 10 billion of offer to repurchases. This approval is not withstanding the current 4.4 billion in share repurchase approval as of 2017. 2018 aggregate incomes direction of 21.8-22.8 billion.

Revenue (USD Million): 22849

R&D Expenses (USD Million): 3562

Annual Revenue Growth: -1%

9. Gilead Sciences

Research-based Pharma company, Gilead, is one of the largest pharma companies in the world.

Image: company website

In 2016, the affiliation extended administrative guaranteeing for Vemlidy, which is used to treat hepatitis B defilement disorders. Obviously, Gilead concentrated on influencing antiviral medications for convincing ailments to like HIV and hepatitis B/C, in any case, the affiliation has fanned out into different districts, for example, aspiratory distresses. Despite the fact that 2016 antiviral remedy game plans addressed 90% of aggregate pay, the total gathered from other pharmaceutical courses of action has moved by 13.6% since 2015. Signify wages for the last quarter of 2017 were 5.9 billion appeared differently in relation to 7.3 billion for a comparative period in 2016. Net incident for the last quarter of 2017 was 3.9 billion, or 2.96 hardship per share, stood out from net pay of 3.1 billion, or 2.34 per debilitated offer for a comparable period in 2016. The net incident for the last quarter consolidates a normal 5.5 billion accuse distinguished of the foundation of the Tax Cuts and Jobs Act (Tax Reform). Net pay for the last quarter of 2017 was 2.3 billion, or 1.78 per offer, stood out from 3.6 billion, or 2.70 per debilitated offer for a comparable period in 2016. Net pay denies wholes related to obtainment related, ahead of time joint exertion, stock-based pay and diverse expenses, and the impact of Tax Reform. Full year 2017 total wages were 26.1 billion, stood out from 30.4 billion for 2016. Net wage for 2017 was 4.6 billion, or 3.51 per debilitated offer, appeared differently in relation to 13.5 billion, or 9.94 per debilitated offer for 2016.

Revenue (USD Million): 25662

R&D Expenses (USD Million): 3374

Annual Revenue Growth: -15%

8. GlaxoSmithKline

GlaxoSmithKline is an English pharmaceutical organization which is known worldwide for its medicines and other products.


The expansion can be credited to the superb execution of HIV drugs Trivicay and Triumeq, and solid immunization deals, especially the meningitis and influenza antibody. The organization prides itself on its wide helpful effort that highlights a solid pipeline of inventive medications and treatments inside zones, for example, neurology, oncology, respiratory and immuno-aggravation. In 2016, GSK's then-CEO Andrew Witty trusts that the year's execution was because of "ventures we made to manufacture new scale and supportability in the gathering and to grow new items" and would like to see this achievement proceed into 2017. GSK has several brands in consumer healthcare as well. The company has been listed on New York Stock Exchange, London Stock Exchange as well as FTSE Index. Close to 100,000+ people are employed in the company.

Revenue (USD Million): 24038

R&D Expenses (USD Million): 6235

Annual Revenue Growth: 7%

7. AbbVie

AbbVie is an American biopharmaceutical affiliation that addresses noteworthy master in making little particle drugs for patients around the world.

Image: company website

Another region into ProClinical's best 10 pharma list, the affiliation is popular for working up the most elevated purpose of the line calm, Humira, which is utilized to treat rheumatoid joint disturbance. The affiliation additionally rotates around other treatment zones, for example, dermatology, oncology, neurological disarranges and metabolic infirmities. AbbVie owes a lot of its thriving this year to the standard degree of general best offering drugs, for example, Humira and Imbruvica, notwithstanding the way that Lupron, Veikira and Synthroid have additionally acknowledged an area in boosting wage. The midpoint of this heading reflects year-over-year advancement of 32 percent, most of which is driven by improvement in the central business. In regard to the in advance issued 2018 bearing gave in October 2017, this course fuses a development of 0.08 in view of more grounded working components. AbbVie's adjusted Earnings per share course go mirrors a suitable evaluation rate of about 9 percent in 2018. In 2018, AbbVie will experience a one-time net tax reduction related to the arranging of the phase in of courses of action of the new sanctioning on particular assistants. AbbVie speculates the association's adjusted intense appraisal rate to augmentation to 13 percent all through the accompanying 5 years in light of extended nearby wage and wander.

Revenue (USD Million): 28216

R&D Expenses (USD Million): 4982

Annual Revenue Growth: 10.39%

6. Novartis

The Swiss pharmaceutical Company, Novartis, makes or produces the pharmaceutical products in the zones/area of medicines, pharma products etc.

Image: Wikimedia

2016 noticed a slight dunk in show progression from the earlier year, however the affiliation checked this hardship by uncovering some basic inside changes to help future game plans. Such as an example, Novartis split their pharmaceutical unit in two, with one being only focused around oncology – a region of phenomenal concentration that they have to widen going advances. On the other hand Cosentyx was an important achievement in the year 2016 and bits of knowledge at no help off in 2017. Novartis passed on best execution in 2017 as strong offers of our advancement key drivers, including Cosentyx, Entresto, Promacta/Revolade, and Tafinlar + Mekinist, continued adjusting the impact of non particular contention for our tumor sedate Gleevec/Glivec. Our results underscore the extensiveness and nature of our thing portfolio and highlight our success at controlling through patent terminations. Arrangements extended in the Innovative Medicines Division and the Alcon eye mind division returned to improvement. Sandoz Division bargains declined due to extended esteem contention in the US. Novartis net arrangements were USD 49.1 billion, up 1% in declared terms and up 2% in enduring money related structures. Arrangements volumes extended 7%, more than adjusting the impact of patent breaches. Working compensation in 2017 was USD 8.6 billion, basically it is controlled by higher arrangements, benefit changes and lower amortization, which were not entirely offset flat contention and higher publicizing wanders. Net wage was USD 7.7 billion benefitting from improvement in working pay and pay from related associations. Benefit per share were USD 3.28 benefitting from higher net pay and our offer buyback program.

Revenue (USD Million): 33000

R&D Expenses (USD Million): 8972

Annual Revenue Growth: 1.35%

5. Sanofi

Sanofi is one of the largest pharmaceutical companies in the world having a global presence.

Image: Wikimedia

Sanofi is a French pharmaceutical organization that spotlights on creating and assembling treatments for some of the present greatest worldwide medical problems. Headquartered in Paris, France, the company has a strong workforce with over 100,000+ employees. The company covers main medicinal areas like cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. The organization picked up FDA endorsement for once-day by day insulin infusion Soliqua for patients with type 2 diabetes, while blockbuster sedate Lantus (diabetes and cardiovascular) encountered a plunge in deals contrasted and 2015. Although, the diabetes and the cardiovascular fragment grew by 3.8%, close by Sanofi Genzyme (strength mind) which expanded by 12.6 percent and also the Rare Disease Franchise by 9.7 percent.

Revenue (USD Million): 36663

R&D Expenses (USD Million): 6697

Annual Revenue Growth: 4.2%

4. Merck & Co

In like manner making profit this year, Merck and Co is a US pharmaceutical company headquartered in New Jersey.


Regardless of the way that the association did not experience an extensive hop in pay differentiated and 2015 figures, Merck has kept up continuing business part improvement all through 2016 and into 2017. Amazingly, their non-little cell threat sedate Keytruda expanded regulatory underwriting from the FDA and EMA. It is depended upon to be an 'unmistakable preferred standpoint' for lung development patients around the globe. Expects Full-Year 2018 Worldwide Sales to be Between 41.2 Billion and 42.7 Billion, also including an approximately 1 Percent Positive and good Impact from Foreign Exchange. The Earnings per share is expected to be between 2.97 and 3.12. 70,000+ employees are with the organization Merck, the company which was established in 1917.

Revenue (USD Million): 35390

R&D Expenses (USD Million): 10000

Annual Revenue Growth: 1%

3. Johnson & Johnson

With about 20 billion more and higher in wage, Johnson and Johnson is by a long shot the world's most prominent pharmaceutical relationship in light of compensation.


The US pharmaceutical, helpful contraptions and buyer flourishing supplier is a since quite a while earlier settled easily apparent name, with staple things. For example, Aveeno, Johnson's Baby and Clean and Clear overwhelming the customer stock advance. Wage has stretched out, to a confined degree, in perspective of a 6.5% ascending in pharmaceutical courses of action regardless of the way that an immense essential bit of the affiliation's focal points is from their buyer flourishing partition. The lift in pharmaceutical game plans is for the most part an immediate aftereffect of the stellar execution of illness steady Imbruvica, which is up by 86%. Like Pfizer, J&J have united a superior than normal year with an especially sorted out 30 billion mergers with Swiss biopharma Actelion. General arrangements for the whole year 2017 were 76.5 billion, an extension of 6.3% versus 2016. Operational results extended 6.0% and the beneficial outcome of cash was 0.3%. Family unit bargains extended 5.4%. All-inclusive arrangements extended 7.4%, reflecting operational advancement of 6.6% and a positive cash impact of 0.8%. Notwithstanding the net impact of acquisitions and divestitures, on an operational introduce, general arrangements for the whole year 2017 extended 2.4%, family unit bargains extended 1.6% and overall arrangements extended 3.3%. Net pay and debilitated benefit per share for the whole year 2017 were 1.3 billion and 0.47, independently. Whole year net salary included after-evaluate unimportant amortization cost of around 2.5 billion and a charge for after-force exceptional things of generally 16.2 billion. Consolidated into these uncommon things is a transitory measure of around 13.6 billion related with the present foundation of cost establishment.

Revenue (USD Million): 36256

R&D Expenses (USD Million): 10554

Annual Revenue Growth: 8.3%

2. Roche

Among the primary 3 pharmaceutical associations of 2017 is another Swiss-based pharma company, F. Hoffmann-La Roche Ltd.

Image: company website

The association makes drugs and symptomatic instruments and has a proximity in Europe, North America, South America and Asia. The present year's success is owed to creating offers of top notch drugs, Herceptin, Kadcyla and Perjeta that extended by 4%, 7% and 26% independently. The association is in like manner planning to push some new propel solutions into the market all through the accompanying couple of years, including much-expected Ocrevus that will be used to treat various sclerosis. Hoffmann-La (Roche) is an exploration centered human services organization that creates, makes and conveys inventive therapeutics and indicative instruments and tests. Roche offers medication in various categories i.e. oncology, diabetes, ophthalmology, neuroscience, immunology, and irresistible illnesses. In 2017, top 3 top rated drugs incorporate malignancy medicines MabThera/Rituxan, Herceptin, and Perjeta.

Revenue (USD Million): 44368

R&D Expenses (USD Million): 10329

Annual Revenue Growth: 12%

1. Pfizer

The next place, American company Pfizer is ranked 1 and it is one of the biggest pharma companies globally.


The organization bases on a broad assortment of treatment areas including oncology, neuroscience, metabolic ailments and exceptional ailment, and furthermore making vaccinations. Extended pay can be associated with the tremendous advancement of a couple of solutions which includes chest malady, Lyrica (misery) and Eliquis (blood thinner) that additional to a general 5% move up in bargains. In like manner, Pfizer got a little pharmaceutical association arranged in California, that is depended upon to help the pharma mammoth's disturbance and immunology portfolio in the coming years. 2017 earning of 52 Billion shows the strong position of the company. Revenues were also increased by 2% operationally. The Final Quarter of 2017 earnings of 13+ Billion increased substantially, which shows the consistence performance of the brand. 2018 revenue Growth of 4% and Adjusted Diluted Earnings per share Growth of 11% show a strong financial performance forecasting for the company.

Revenue (USD Million): 52540

R&D Expenses (USD Million): 7657

Annual Revenue Growth: -0.53%

Rank Methodology:

1. The leading pharmaceutical companies in the world are considered.

2. Parameters like revenues, R&D expenditure and growth rate are considered and given 40%, 50% and 10% weightages respectively.

3. A final score is calculated and the ranks are evaluated.

Looking for Similar Lists, Browse more Top Lists

Share this Page on:
Facebook ShareTweetShare on Linkedin